EKF Stock Overview
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally.
EKF Diagnostics Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.35|
|52 Week High||UK£0.87|
|52 Week Low||UK£0.33|
|1 Month Change||-6.67%|
|3 Month Change||-31.37%|
|1 Year Change||-54.78%|
|3 Year Change||5.10%|
|5 Year Change||70.73%|
|Change since IPO||-15.66%|
Recent News & Updates
Some EKF Diagnostics Holdings plc (LON:EKF) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for EKF Diagnostics Holdings plc ( LON:EKF ) shareholders, with the analysts delivering a...
|EKF||GB Medical Equipment||GB Market|
Return vs Industry: EKF underperformed the UK Medical Equipment industry which returned -17.2% over the past year.
Return vs Market: EKF underperformed the UK Market which returned -2.7% over the past year.
|EKF Average Weekly Movement||8.8%|
|Medical Equipment Industry Average Movement||6.2%|
|Market Average Movement||6.0%|
|10% most volatile stocks in GB Market||11.6%|
|10% least volatile stocks in GB Market||3.1%|
Stable Share Price: EKF is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: EKF's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer.
EKF Diagnostics Holdings Fundamentals Summary
|EKF fundamental statistics|
Is EKF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EKF income statement (TTM)|
|Cost of Revenue||UK£42.47m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.035|
|Net Profit Margin||19.37%|
How did EKF perform over the long term?See historical performance and comparison
3.4%Current Dividend Yield
Is EKF Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EKF (£0.35) is trading below our estimate of fair value (£0.91)
Significantly Below Fair Value: EKF is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EKF is good value based on its Price-To-Earnings Ratio (10x) compared to the UK Medical Equipment industry average (26.9x).
PE vs Market: EKF is good value based on its Price-To-Earnings Ratio (10x) compared to the UK market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: EKF's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: EKF is good value based on its Price-To-Book Ratio (1.7x) compared to the GB Medical Equipment industry average (2.8x).
How is EKF Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EKF's earnings are forecast to decline over the next 3 years (-9.9% per year).
Earnings vs Market: EKF's earnings are forecast to decline over the next 3 years (-9.9% per year).
High Growth Earnings: EKF's earnings are forecast to decline over the next 3 years.
Revenue vs Market: EKF's revenue (0.06% per year) is forecast to grow slower than the UK market (4% per year).
High Growth Revenue: EKF's revenue (0.06% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EKF's Return on Equity is forecast to be low in 3 years time (11.1%).
How has EKF Diagnostics Holdings performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EKF has high quality earnings.
Growing Profit Margin: EKF's current net profit margins (19.4%) are higher than last year (17%).
Past Earnings Growth Analysis
Earnings Trend: EKF has become profitable over the past 5 years, growing earnings by 39.7% per year.
Accelerating Growth: EKF's earnings growth over the past year (42.6%) exceeds its 5-year average (39.7% per year).
Earnings vs Industry: EKF earnings growth over the past year (42.6%) exceeded the Medical Equipment industry 22.3%.
Return on Equity
High ROE: EKF's Return on Equity (17.1%) is considered low.
How is EKF Diagnostics Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: EKF's short term assets (£47.6M) exceed its short term liabilities (£13.7M).
Long Term Liabilities: EKF's short term assets (£47.6M) exceed its long term liabilities (£6.7M).
Debt to Equity History and Analysis
Debt Level: EKF has more cash than its total debt.
Reducing Debt: EKF's debt to equity ratio has reduced from 8.6% to 0.7% over the past 5 years.
Debt Coverage: EKF's debt is well covered by operating cash flow (1471%).
Interest Coverage: EKF's interest payments on its debt are well covered by EBIT (949.7x coverage).
What is EKF Diagnostics Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EKF's dividend (3.43%) is higher than the bottom 25% of dividend payers in the UK market (1.78%).
High Dividend: EKF's dividend (3.43%) is low compared to the top 25% of dividend payers in the UK market (4.85%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, EKF has been paying a dividend for less than 10 years.
Growing Dividend: EKF's dividend payments have increased, but the company has only paid a dividend for 2 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (34.6%), EKF's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (119%), EKF's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Salter (60 yo)
Mr. David Michael Salter, also known as Mike, has been Executive Director at EKF Diagnostics Holdings plc since August 2021 and its Chief Executive Officer since October 1, 2021. He was Head of US operatio...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD328.01K) is below average for companies of similar size in the UK market ($USD663.05K).
Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.
Experienced Management: EKF's management team is considered experienced (3.4 years average tenure).
Experienced Board: EKF's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EKF Diagnostics Holdings plc's employee growth, exchange listings and data sources
- Name: EKF Diagnostics Holdings plc
- Ticker: EKF
- Exchange: AIM
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: UK£159.226m
- Shares outstanding: 454.93m
- Website: https://www.ekfdiagnostics.com
Number of Employees
- EKF Diagnostics Holdings plc
- Avon House
- 19 Stanwell Road
- South Glamorgan
- CF64 2EZ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.